the 21st century
Opening up new opportunities for patients, doctors and clinics.
What is DISQVER?
Conventional diagnostic methods based on blood cultures usually require from two days to several weeks to identify a limited set of pathogens. Noscendo’s DISQVER platform identifies more than 16,000 microbes including 1,500 described pathogens (bacteria, DNA viruses, fungi and parasites) within 24 hours.
The cell-free DNA in the patient’s blood is determined using next-generation sequencing (NGS), a new, exceptionally fast method for DNA analysis. DISQVER’s bioinformatics algorithms compare this information against Noscendo clinical grade genome reference database. A report detailing all relevant pathogens detected in the sample is provided within a few hours. This knowledge can be used for blood stream infections and sepsis, in oncological diagnostics or diagnostics for endocarditis, for example.
Test DISQVER now!
Would you like to find out more or test DISQVER in your clinic?
ADVANTAGES OF DISQVER
AT A GLANCE
Cell-free DNA as new and more abundant biomarker allows precise analysis of the microbial load at the time of blood collection
Detects bacteria, fungi, DNA viruses and parasites from a standard blood sample using next-generation sequencing
Reliably identifies difficult and non-cultivatable pathogens
Independent of an already started anti-infective therapy
Without prior cultivation or prior knowledge of the possible cause of infection
Reliable statement on the exclusion of an infection
How DISQVER works
About noscendo
Noscendo is the leading global provider of software-based pathogen identification technology. We’ve made it our objective to revolutionise infection diagnostics, thus saving patient lives. To do so, we combine the latest molecular biology methods, such as next-generation sequencing (NGS), with proprietary bio IT solutions in our analysis platform DISQVER. Scores of well-known university hospitals, major regional hospitals and hospital groups are already using DISQVER. We also work with health insurance providers such as TK and IKK Südwest.
News
Noscendo presents DISQVER® at HAI 2022, the 24th Capital Congress of the DGAI for Anaesthesiology and Intensive Care Therapy
After a pandemic-related break, the 24th Capital Congress of the German Society for Anaesthesiology & Intensive Care Medicine (DGAI) will be held again this year in presence. From September 14-17, the focus will be on medical advances in anaesthesia, intensive...
Potential impact of cell-free DNA blood testing in the diagnosis of sepsis
Next-Generation Sequencing-Based Decision Support for Intensivists in Difficult-to-Diagnose Disease States
Software driven NGS-based diagnostics company Noscendo secures funding to revolutionize the diagnosis of infectious diseases
Series B led by a renowned family office focused on life sciences, with impact-focused VC Revent as co-investor, plus support from existing investorsFurther development of proprietary DISQVER® technology and international expansion Duisburg, May 16, 2022 –...
More precise diagnostics, more knowledge
Noscendo’s DISQVER platform compares cell-free DNA determined from the patient sample using next-generation sequencing with a clinical genome database. This makes it possible to identify harmful pathogens that cannot be verified using conventional methods.
Within 24 hours, DISQVER can identify:
microbes
pathogens
viruses
bacteria
fungi
parasites
